Skip to main content
SpringerLink
Log in

Bisphosphonates – Treatment of Osteoporosis

  • Chapter
  • First Online:
Osteoporosis

Part of the book series: Contemporary Endocrinology ((COE))

  • 865 Accesses

Abstract

Bisphosphonates are inorganic pyrophosphate (P–O–P) analogues, in which the bridging oxygen atom is replaced by carbon. The P–C–P moiety is responsible for the binding of bisphosphonates to hydroxyapatite bone mineral surfaces (1). Bisphosphonates can be grouped into two main groups, depending whether or not they contain a nitrogen side chain. Non-nitrogen-containing bisphosphonates include etidronate, tiludronate, and clodronate (2). Nitrogen-containing bisphosphonates such as alendronate, risedronate, zolendronate, pamidronate, and ibandronate are more potent than non-nitrogen bisphosphonates.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  1. Rodan GA, Reszka AA. Osteoporosis and bisphosphonates. J Bone Joint Surg Am 2003;85-A(Suppl 3):8–12.

    PubMed  Google Scholar 

  2. Reszka AA, Rodan GA. Nitrogen-containing bisphosphonate mechanism of action. Mini-Rev Med Chem 2004;4(7):711–719.

    PubMed  CAS  Google Scholar 

  3. Russell RG. Bisphosphonates: from bench to bedside. Ann N Y Acad Sci 2006;1068:367–401.

    Article  PubMed  CAS  Google Scholar 

  4. Brown JP, Chines AA, Myers WR, Eusebio RA, Ritter-Hrncirik C, Hayes CW. Improvement of pagetic bone lesions with risedronate treatment: a radiologic study. Bone 2000;26(3):263–267.

    Article  PubMed  CAS  Google Scholar 

  5. Hosking D, Lyles K, Brown JP, Fraser WD, Miller P, Diaz CM, et al. Long-term control of bone turnover in Paget’s disease with zoledronic acid and risedronate. J Bone Miner Res 2007;22(1):142–148.

    Article  PubMed  CAS  Google Scholar 

  6. Reid IR, Miller P, Lyles K, Fraser W, Brown JP, Saidi Y, et al. Comparison of a single infusion of zoledronic acid with risedronate for Paget’s disease. N Engl J Med 2005;353(9):898–908.

    Article  PubMed  CAS  Google Scholar 

  7. Chapurlat RD, Hugueny P, Delmas PD, Meunier PJ. Treatment of fibrous dysplasia of bone with intravenous pamidronate: long-term effectiveness and evaluation of predictors of response to treatment. Bone 2004;35(1):235–242.

    Article  PubMed  CAS  Google Scholar 

  8. Chapurlat RD. Medical therapy in adults with fibrous dysplasia of bone. J Bone Miner Res 2006;21(Suppl 2):114–119.

    Article  Google Scholar 

  9. Adachi JD, Roux C, Pitt PI, Cooper C, Moniz C, Dequeker J, et al. A pooled data analysis on the use of intermittent cyclical etidronate therapy for the prevention and treatment of corticosteroid induced bone loss. J Rheumatol 2000;27(10):2424–2431.

    PubMed  CAS  Google Scholar 

  10. Adachi JD, Bensen WG, Brown J, Hanley D, Hodsman A, Josse R, et al. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 1997;337(6):382–387.

    Article  PubMed  CAS  Google Scholar 

  11. Saag KG. Glucocorticoid-induced osteoporosis. Endocrinol Metab Clin North Am 2003;32(1):135–157.

    Article  PubMed  CAS  Google Scholar 

  12. McCloskey EV, Dunn JA, Kanis JA, MacLennan IC, Drayson MT. Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma. Br J Haematol 2001;113(4):1035–1043.

    Article  PubMed  CAS  Google Scholar 

  13. Kanis JA, Powles T, Paterson AH, McCloskey EV, Ashley S. Clodronate decreases the frequency of skeletal metastases in women with breast cancer. Bone 1996;19(6):663–667.

    Article  PubMed  CAS  Google Scholar 

  14. Lai KA, Shen WJ, Yang CY, Shao CJ, Hsu JT, Lin RM. The use of alendronate to prevent early collapse of the femoral head in patients with nontraumatic osteonecrosis. A randomized clinical study. J Bone Joint Surg Am 2005;87(10):2155–2159.

    Article  PubMed  Google Scholar 

  15. Wilkinson JM, Eagleton AC, Stockley I, Peel NF, Hamer AJ, Eastell R. Effect of pamidronate on bone turnover and implant migration after total hip arthroplasty: a randomized trial. J Orthop Res 2005;23(1):1–8.

    Article  PubMed  CAS  Google Scholar 

  16. Watts NB, Harris ST, Genant HK, Wasnich RD, Miller PD, Jackson RD, et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 1990;323(2):73–79.

    Article  PubMed  CAS  Google Scholar 

  17. Storm T, Thamsborg G, Steiniche T, Genant HK, Sorensen OH. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 1990;322(18):1265–1271.

    Article  PubMed  CAS  Google Scholar 

  18. Cranney A, Guyatt G, Krolicki N, Welch V, Griffith L, Adachi JD, et al. A meta-analysis of etidronate for the treatment of postmenopausal osteoporosis. Osteoporos Int 2001;12(2):140–151.

    Article  PubMed  CAS  Google Scholar 

  19. Kanis JA, McCloskey EV. Clodronate. Cancer 1997;80(8 Suppl):1691–1695.

    Article  PubMed  CAS  Google Scholar 

  20. Filipponi P, Cristallini S, Policani G, Schifini MF, Casciari C, Garinei P. Intermittent versus continuous clodronate administration in postmenopausal women with low bone mass. Bone 2000;26(3):269–274.

    Article  PubMed  CAS  Google Scholar 

  21. Filipponi P, Cristallini S, Rizzello E, Policani G, Fedeli L, Gregorio F, et al. Cyclical intravenous clodronate in postmenopausal osteoporosis: results of a long-term clinical trial. Bone 1996;18(2):179–184.

    Article  PubMed  CAS  Google Scholar 

  22. McCloskey EV, Beneton M, Charlesworth D, Kayan K, Detakats D, Dey A, et al. Clodronate reduces the incidence of fractures in community-dwelling elderly women unselected for osteoporosis: results of a double-blind, placebo-controlled randomized study. J Bone Miner Res 2007;22(1):135–141.

    Article  PubMed  CAS  Google Scholar 

  23. Cauza E, Etemad M, Winkler F, Hanusch-Enserer H, Partsch G, Noske H, et al. Pamidronate increases bone mineral density in women with postmenopausal or steroid-induced osteoporosis. J Clin Pharm Ther 2004;29(5):431–436.

    Article  PubMed  CAS  Google Scholar 

  24. Coukell AJ, Markham A. Pamidronate. A review of its use in the management of osteolytic bone metastases, tumour-induced hypercalcaemia and Paget’s disease of bone. Drugs Aging 1998;12(2):149–168.

    Article  PubMed  CAS  Google Scholar 

  25. Brumsen C, Papapoulos SE, Lips P, Geelhoed-Duijvestijn PH, Hamdy NA, Landman JO, et al. Daily oral pamidronate in women and men with osteoporosis: a 3-year randomized placebo-controlled clinical trial with a 2-year open extension. J Bone Miner Res 2002;17(6):1057–1064.

    Article  PubMed  CAS  Google Scholar 

  26. Peretz A, Body JJ, Dumon JC, Rozenberg S, Hotimski A, Praet JP, et al. Cyclical pamidronate infusions in postmenopausal osteoporosis. Maturitas 1996;25(1):69–75.

    Article  PubMed  CAS  Google Scholar 

  27. Lees B, Garland SW, Walton C, Ross D, Whitehead MI, Stevenson JC. Role of oral pamidronate in preventing bone loss in postmenopausal women. Osteoporos Int 1996;6(6):480–485.

    Article  PubMed  CAS  Google Scholar 

  28. Boutsen Y, Jamart J, Esselinckx W, Devogelaer JP. Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone. J Bone Miner Res 2001;16(1):104–112.

    Article  PubMed  CAS  Google Scholar 

  29. Lourwood DL. The pharmacology and therapeutic utility of bisphosphonates. Pharmacotherapy 1998;18(4):779–789.

    PubMed  CAS  Google Scholar 

  30. Porras AG, Holland SD, Gertz BJ. Pharmacokinetics of alendronate. Clin Pharmacokinet 1999;36(5):315–328.

    Article  PubMed  CAS  Google Scholar 

  31. Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 1995;333(22):1437–1443.

    Article  PubMed  CAS  Google Scholar 

  32. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;348(9041):1535–1541.

    Article  PubMed  CAS  Google Scholar 

  33. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998;280(24):2077–2082.

    Article  PubMed  CAS  Google Scholar 

  34. Papapoulos SE, Quandt SA, Liberman UA, Hochberg MC, Thompson DE. Meta-analysis of the efficacy of alendronate for the prevention of hip fractures in postmenopausal women. Osteoporos Int 2005;16(5):468–474.

    Article  PubMed  CAS  Google Scholar 

  35. Liberman UA, Hochberg MC, Geusens P, Shah A, Lin J, Chattopadhyay A, et al. Hip and non-spine fracture risk reductions differ among antiresorptive agents: Evidence from randomised controlled trials. Int J Clin Pract 2006;60(11):1394–1400.

    Article  PubMed  CAS  Google Scholar 

  36. Bauer DC, Garnero P, Hochberg MC, Santora A, Delmas P, Ewing SK, et al. Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the fracture intervention trial. J Bone Miner Res 2006;21(2):292–299.

    Article  PubMed  CAS  Google Scholar 

  37. Rizzoli R, Greenspan SL, Bone G III, Schnitzer TJ, Watts NB, Adami S, et al. Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis. J Bone Miner Res 2002;17(11):1988–1996.

    Article  PubMed  CAS  Google Scholar 

  38. Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino RP, et al. Ten years’ experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004;350(12):1189–1199.

    Article  PubMed  CAS  Google Scholar 

  39. Ensrud KE, Barrett-Connor EL, Schwartz A, Santora AC, Bauer DC, Suryawanshi S, et al. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension. J Bone Miner Res 2004;(8):1259–1269.

    Google Scholar 

  40. Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 2006;296(24):2927–2938.

    Article  PubMed  CAS  Google Scholar 

  41. Greenspan SL, Emkey RD, Bone HG, Weiss SR, Bell NH, Downs RW, et al. Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial. [summary for patients in Ann Intern Med. 2002;137(11):I31; PMID: 12459003]. Ann Intern Med 2002;137(11):875–883.

    Google Scholar 

  42. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999;282(14):1344–1352.

    Article  PubMed  CAS  Google Scholar 

  43. Reginster JY. Risedronate increases bone mineral density and reduces the vertebral fracture incidence in postmenopausal women. Clin Exp Rheumatol 2001;19(2):121–122.

    PubMed  CAS  Google Scholar 

  44. McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001;344(5):333–340.

    Article  PubMed  CAS  Google Scholar 

  45. Harrington JT, Ste-Marie LG, Brandi ML, Civitelli R, Fardellone P, Grauer A, et al. Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis. Calcif Tissue Int 2004;74(2):129–135.

    Article  PubMed  CAS  Google Scholar 

  46. Adachi JD, Rizzoli R, Boonen S, Li Z, Meredith MP, Chesnut CH III. Vertebral fracture risk reduction with risedronate in post-menopausal women with osteoporosis: a meta-analysis of individual patient data. Aging Clin Exp Res 2005;17(2):150–156.

    PubMed  CAS  Google Scholar 

  47. Cranney A, Tugwell P, Adachi J, Weaver B, Zytaruk N, Papaioannou A, et al. Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. [Review] [21 refs]. Endocr Rev 2002;23(4):517–523.

    Article  PubMed  CAS  Google Scholar 

  48. Sorensen OH, Crawford GM, Mulder H, Hosking DJ, Gennari C, Mellstrom D, et al. Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience. Bone 2003;32(2):120–126.

    Article  PubMed  CAS  Google Scholar 

  49. Mellstrom DD, Sorensen OH, Goemaere S, Roux C, Johnson TD, Chines AA. Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif Tissue Int 2004;75(6):462–468.

    Article  PubMed  CAS  Google Scholar 

  50. Ste-Marie LG, Sod E, Johnson T, Chines A. Five years of treatment with risedronate and its effects on bone safety in women with postmenopausal osteoporosis. Calcif Tissue Int 2004;75(6):469–476.

    Article  PubMed  CAS  Google Scholar 

  51. Miller PD, Roux C, Boonen S, Barton IP, Dunlap LE, Burgio DE. Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials. J Bone Miner Res 2005;20(12):2105–2115.

    Article  PubMed  CAS  Google Scholar 

  52. Watts NB, Chines A, Olszynski WP, McKeever CD, McClung MR, Zhou X, et al. Fracture risk remains reduced one year after discontinuation of risedronate. Osteoporos Int 2008;19(3):365–372.

    Google Scholar 

  53. Brown JP, Kendler DL, McClung MR, Emkey RD, Adachi JD, Bolognese MA, et al. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int 2002;71(2):103–111.

    Article  PubMed  CAS  Google Scholar 

  54. Delmas PD, McClung MR, Zanchetta JR, Racewicz A, Roux C, Benhamou CL, et al. Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis. Bone 2008;42(1):36–42.

    Google Scholar 

  55. Pyon EY. Once-monthly ibandronate for postmenopausal osteoporosis: review of a new dosing regimen. Clin Ther 2006;28(4):475–490.

    Article  PubMed  CAS  Google Scholar 

  56. Stakkestad JA, Benevolenskaya LI, Stepan JJ, Skag A, Nordby A, Oefjord E, et al. Intravenous ibandronate injections given every three months: a new treatment option to prevent bone loss in postmenopausal women [see comment]. Ann Rheum Dis 2003;62(10):969–975.

    Article  PubMed  CAS  Google Scholar 

  57. McClung MR, Wasnich RD, Recker R, Cauley JA, Chesnut CH III, Ensrud KE, et al. Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis. J Bone Miner Res 2004;1:11–18.

    Google Scholar 

  58. Chesnut CH III, Skag A, Christiansen C, Recker R, Stakkestad JA, Hoiseth A, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004;8:1241–1249.

    Article  CAS  Google Scholar 

  59. Recker R, Stakkestad JA, Chesnut CH III, Christiansen C, Skag A, Hoiseth A, et al. Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis. Bone 2004;34(5):890–899.

    Article  PubMed  CAS  Google Scholar 

  60. Miller PD, McClung MR, Macovei L, Stakkestad JA, Luckey M, Bonvoisin B, et al. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res 2005;20(8):1315–1322.

    Article  PubMed  CAS  Google Scholar 

  61. Delmas PD, Adami S, Strugala C, Stakkestad JA, Reginster JY, Felsenberg D, et al. Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis Rheum 2006;54(6):1838–1846.

    Article  PubMed  CAS  Google Scholar 

  62. Ravn P, Neugebauer G, Christiansen C. Association between pharmacokinetics of oral ibandronate and clinical response in bone mass and bone turnover in women with postmenopausal osteoporosis. Bone 2002;30(1):320–324.

    Article  PubMed  CAS  Google Scholar 

  63. Adami S, Felsenberg D, Christiansen C, Robinson J, Lorenc RS, Mahoney P, et al. Efficacy and safety of ibandronate given by intravenous injection once every 3 months. Bone 2004;34(5):881–889.

    Article  PubMed  CAS  Google Scholar 

  64. Riis BJ, Ise J, von Stein T, Bagger Y, Christiansen C. Ibandronate: a comparison of oral daily dosing versus intermittent dosing in postmenopausal osteoporosis. J Bone Miner Res 2001;16(10):1871–1878.

    Article  PubMed  CAS  Google Scholar 

  65. Thiebaud D, Burckhardt P, Kriegbaum H, Huss H, Mulder H, Juttmann JR, et al. Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis. Am J Med 1997;103(4):298–307.

    Article  PubMed  CAS  Google Scholar 

  66. Reginster JY, Adami S, Lakatos P, Greenwald M, Stepan JJ, Silverman SL, et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2-year results from the MOBILE study. Ann Rheum Dis 2006;65(5):654–661.

    Google Scholar 

  67. Reid IR, Brown JP, Burckhardt P, Horowitz Z, Richardson P, Trechsel U, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002;346(9):653–661.

    Article  PubMed  CAS  Google Scholar 

  68. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, et al. Once-yearly zoledronic acid 5 mg for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356(18):1809–1822.

    Article  PubMed  CAS  Google Scholar 

  69. Lyles KW, Colon-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, et al. Zoledronic Acid and Clinical Fractures and Mortality after Hip Fracture. N Engl J Med 2007;357:1799–1809.

    Google Scholar 

  70. Rosen CJ, Hochberg MC, Bonnick SL, McClung M, Miller P, Broy S, et al. Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study. J Bone Miner Res 2005;20(1):141–151.

    Article  PubMed  CAS  Google Scholar 

  71. Bonnick S, Saag KG, Kiel DP, McClung M, Hochberg M, Burnett SA, et al. Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years. J Clin Endocrinol Metab 2006;91(7):2631–2637.

    Article  PubMed  CAS  Google Scholar 

  72. Wehren LE, Hosking D, Hochberg MC. Putting evidence-based medicine into clinical practice: comparing anti-resorptive agents for the treatment of osteoporosis. Curr Med Res Opin 2004;20(4):525–531.

    Article  PubMed  Google Scholar 

  73. Silverman SL, Watts NB, Delmas PD, Lange JL, Lindsay R. Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: The risedronate and alendronate (REAL) cohort study. Osteoporos Int 2007;18(1):25–34.

    Article  PubMed  CAS  Google Scholar 

  74. Black DM, Rosen CJ. Is risedronate or alendronate more effective at preventing nonvertebral fractures in women with osteoporosis? Nat Clin Pract Rheumatol 2007;3(7):378–379.

    Article  PubMed  CAS  Google Scholar 

  75. Wasnich RD, Miller PD. Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab 2000;85(1):231–236.

    Article  PubMed  CAS  Google Scholar 

  76. Hochberg MC, Ross PD, Black D, Cummings SR, Genant HK, Nevitt MC, et al. Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group. Arthritis Rheum 1999;42(6):1246–1254.

    Article  PubMed  CAS  Google Scholar 

  77. Watts NB, Cooper C, Lindsay R, Eastell R, Manhart MD, Barton IP, et al. Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk. J Clin Densitom 2004;7(3):255–261.

    Article  PubMed  Google Scholar 

  78. Cummings SR, Karpf DB, Harris F, Genant HK, Ensrud K, LaCroix AZ, et al. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 2002;112(4):281–289.

    Article  PubMed  CAS  Google Scholar 

  79. Hochberg MC, Greenspan S, Wasnich RD, Miller P, Thompson DE, Ross PD. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 2002;87(4):1586–1592.

    Article  PubMed  CAS  Google Scholar 

  80. Watts NB, Geusens P, Barton IP, Felsenberg D. Relationship between changes in BMD and nonvertebral fracture incidence associated with risedronate: reduction in risk of nonvertebral fracture is not related to change in BMD. J Bone Miner Res 2005;20(12):2097–2104.

    Article  PubMed  Google Scholar 

  81. Delmas PD, Seeman E. Changes in bone mineral density explain little of the reduction in vertebral or nonvertebral fracture risk with anti-resorptive therapy. Bone 2004;34(4):599–604.

    Article  PubMed  CAS  Google Scholar 

  82. Delmas PD, Li Z, Cooper C. Relationship between changes in bone mineral density and fracture risk reduction with antiresorptive drugs: some issues with meta-analyses. J Bone Miner Res 2004;19(2):330–337.

    Article  PubMed  CAS  Google Scholar 

  83. Bauer DC, Black DM, Garnero P, Hochberg M, Ott S, Orloff J, et al. Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. J Bone Miner Res 2004;8:1250–1258.

    Article  Google Scholar 

  84. Borah B, Dufresne TE, Chmielewski PA, Johnson TD, Chines A, Manhart MD. Risedronate preserves bone architecture in postmenopausal women with osteoporosis as measured by three-dimensional microcomputed tomography. Bone 2004;34(4):736–746.

    Article  PubMed  CAS  Google Scholar 

  85. Recker R, Masarachia P, Santora A, Howard T, Chavassieux P, Arlot M, et al. Trabecular bone microarchitecture after alendronate treatment of osteoporotic women. Curr Med Res Opin 2005;21(2):185–194.

    Article  PubMed  CAS  Google Scholar 

  86. Eastell R, Barton I, Hannon RA, Chines A, Garnero P, Delmas PD. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 2003;18(6):1051–1056.

    Article  PubMed  CAS  Google Scholar 

  87. Greenspan SL, Resnick NM, Parker RA. Combination therapy with hormone replacement and alendronate for prevention of bone loss in elderly women: a randomized controlled trial. JAMA 2003;289(19):2525–2533.

    Article  PubMed  CAS  Google Scholar 

  88. Harris ST, Eriksen EF, Davidson M, Ettinger MP, Moffett JA Jr, Baylink DJ, et al. Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women. J Clin Endocrinol Metab 2001;86(5):1890–1897.

    Article  PubMed  CAS  Google Scholar 

  89. Johnell O, Scheele WH, Lu Y, Reginster JY, Need AG, Seeman E. Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis [see comment]. J Clin Endocrinol Metab 2002;87(3):985–992.

    Article  PubMed  CAS  Google Scholar 

  90. Wimalawansa SJ. A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis. Am J Med 1998;104(3):219–226.

    Article  PubMed  CAS  Google Scholar 

  91. Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 2003;349(13):1207–1215.

    Article  PubMed  CAS  Google Scholar 

  92. Cosman F, Nieves J, Zion M, Woelfert L, Luckey M, Lindsay R. Daily and cyclic parathyroid hormone in women receiving alendronate. N Engl J Med 2005;353(6):566–575.

    Article  PubMed  CAS  Google Scholar 

  93. Canalis E, Giustina A, Bilezikian JP. Mechanisms of anabolic therapies for osteoporosis. N Engl J Med 2007;357(9):905–916.

    Article  PubMed  CAS  Google Scholar 

  94. Tyrrell CJ, Collinson M, Madsen EL, Ford JM, Coleman T. Intravenous pamidronate: infusion rate and safety. Ann Oncol 1994;5(Suppl 7):S27–S29.

    PubMed  Google Scholar 

  95. Rosen CJ, Brown S. Severe hypocalcemia after intravenous bisphosphonate therapy in occult vitamin D deficiency. N Engl J Med 2003;348(15):1503–1504.

    Article  PubMed  Google Scholar 

  96. Champallou C, Basuyau JP, Veyret C, Chinet P, Debled M, Chevrier A, et al. Hypocalcemia following pamidronate administration for bone metastases of solid tumor: three clinical case reports. J Pain Symptom Manage 2003;25(2):185–190.

    Article  PubMed  Google Scholar 

  97. Reid IR, Brown JP, Burckhardt P, Horowitz Z, Richardson P, Trechsel U, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002;346(9):653–661.

    Article  PubMed  CAS  Google Scholar 

  98. Rey J, Daumen-Legre V, Pham T, Bernard P, Dahan L, Acquaviva PC, et al. Uveitis, an under-recognized adverse effect of pamidronate. Case report and literature review. Joint Bone Spine 2000;67(4):337–340.

    PubMed  CAS  Google Scholar 

  99. Stewart GO, Stuckey BG, Ward LC, Prince RL, Gutteridge DH, Constable IJ. Iritis following intravenous pamidronate. Aust N Z J Med 1996;26(3):414–415.

    PubMed  CAS  Google Scholar 

  100. Fraunfelder FW, Fraunfelder FT, Jensvold B. Scleritis and other ocular side effects associated with pamidronate disodium. Am J Ophthalmol 2003;135(2):219–222.

    Article  PubMed  CAS  Google Scholar 

  101. Cummings SR, Schwartz AV, Black DM. Alendronate and atrial fibrillation. N Engl J Med 2007;356(18):1895–1896.

    Article  PubMed  CAS  Google Scholar 

  102. Eisman JA, Rizzoli R, Roman-Ivorra J, Lipschitz S, Verbruggen N, Gaines KA, et al. Upper gastrointestinal and overall tolerability of alendronate once weekly in patients with osteoporosis: results of a randomized, double-blind, placebo-controlled study. Curr Med Res Opin 1920;5:699–705.

    Google Scholar 

  103. Lanza F, Schwartz H, Sahba B, Malaty HM, Musliner T, Reyes R, et al. An endoscopic comparison of the effects of alendronate and risedronate on upper gastrointestinal mucosae. Am J Gastroenterol 2000;95(11):3112–3117.

    Article  PubMed  CAS  Google Scholar 

  104. Lanza FL. Gastrointestinal adverse effects of bisphosphonates: Etiology, incidence and prevention. Treat Endocrinol 2002;1(1):37–43.

    Article  PubMed  Google Scholar 

  105. Taggart H, Bolognese MA, Lindsay R, Ettinger MP, Mulder H, Josse RG, et al. Upper gastrointestinal tract safety of risedronate: A pooled analysis of 9 clinical trials. Mayo Clin Proc 2002;77(3): 262–270.

    Article  PubMed  CAS  Google Scholar 

  106. Cryer B, Bauer DC. Oral bisphosphonates and upper gastrointestinal tract problems: What is the evidence? Mayo Clin Proc 2002;77(10):1031–1043.

    Article  PubMed  Google Scholar 

  107. Bauer DC, Black D, Ensrud K, Thompson D, Hochberg M, Nevitt M, et al. Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial. Arch Intern Med 2000;160(4):517–525.

    Article  PubMed  CAS  Google Scholar 

  108. Li J, Mashiba T, Burr DB. Bisphosphonate treatment suppresses not only stochastic remodeling but also the targeted repair of microdamage. Calcif Tissue Int 2001;69(5):281–286.

    Article  PubMed  CAS  Google Scholar 

  109. Mashiba T, Hui S, Turner CH, Mori S, Johnston CC, Burr DB. Bone remodeling at the iliac crest can predict the changes in remodeling dynamics, microdamage accumulation, and mechanical properties in the lumbar vertebrae of dogs. Calcif Tissue Int 2005;77(3):180–185.

    Article  PubMed  CAS  Google Scholar 

  110. Ott SM. Long-term safety of bisphosphonates. J Clin Endocrinol Metab 2005;90(3):1897–1899.

    Article  PubMed  CAS  Google Scholar 

  111. Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005;90(3):1294–1301.

    Article  PubMed  CAS  Google Scholar 

  112. Recker R, Ensrud K, Diem S, Cheng E, Bare S, Masarachia P, et al. Normal bone histomorphometry and 3D microarchitecture after 10 years alendronate treatment of postmenopausal women. J Bone Miner Res 2004;19:S1–S45. Ref Type: Abstract

    Google Scholar 

  113. Chapurlat RD, Arlot M, Burt-Pichat B, Chavassieux P, Roux JP, Portero-Muzy N, et al. Microcrack frequency and bone remodeling in postmenopausal osteoporotic women on long-term bisphosphonates: a bone biopsy study. J Bone Miner Res 2007;22(10):1502–1509.

    Article  PubMed  CAS  Google Scholar 

  114. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Ten years of alendronate treatment for osteoporosis in postmenopausal women. N Engl J Med 2004;351(2):190–192; author reply.

    Google Scholar 

  115. Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005;63(11):1567–1575.

    Article  PubMed  Google Scholar 

  116. Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006;144(10):753–761.

    PubMed  CAS  Google Scholar 

  117. Carter G, Goss AN, Doecke C. Bisphosphonates and avascular necrosis of the jaw: a possible association. Med J Aust 2005;182(8):413–415.

    PubMed  Google Scholar 

  118. Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a Task Force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007;22(10):1479–1491.

    Google Scholar 

  119. Bilezikian JP. Osteonecrosis of the jaw – do bisphosphonates pose a risk? N Engl J Med 2006;355(22):2278–2281.

    Article  PubMed  CAS  Google Scholar 

  120. Reid IR, Bolland MJ, Grey AB. Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity? Bone 2007;41(3):318–320.

    Article  PubMed  CAS  Google Scholar 

  121. Lenz JH, Steiner-Krammer B, Schmidt W, Fietkau R, Mueller PC, Gundlach KK. Does avascular necrosis of the jaws in cancer patients only occur following treatment with bisphosphonates? J Craniomaxillofac Surg 2005;33(6):395–403.

    PubMed  Google Scholar 

  122. Sambrook P, Olver I, Goss A. Bisphosphonates and osteonecrosis of the jaw. Aust Fam Physician 2006;35(10):801–803.

    PubMed  Google Scholar 

  123. Shane E, Goldring S, Christakos S, Drezner M, Eisman J, Silverman S, et al. Osteonecrosis of the jaw: more research needed. J Bone Miner Res 2006;21(10):1503–1505.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Ottawa Hospital, Ottawa, Ontario, Canada

    Ann Cranney MSC

Authors
  1. Ann Cranney MSC
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Section of Endocrinology, McGuire Veterans Affairs Medical Center, Broad Rock Blvd. 1201, Richmond, 23249, U.S.A.

    Robert A. Adler

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Humana Press, a part of Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Cranney, A. (2010). Bisphosphonates – Treatment of Osteoporosis. In: Adler, R. (eds) Osteoporosis. Contemporary Endocrinology. Humana Press. https://doi.org/10.1007/978-1-59745-459-9_20

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-459-9_20

  • Published:

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-934115-19-0

  • Online ISBN: 978-1-59745-459-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation